It supports tissue repair, reduces inflammation, and accelerates recovery in muscles, tendons, joints, and the gastrointestinal system
When looking at the percentage of participants that dropped out of the trial due to adverse effects, 2-6% of patients in the cagrilintide group discontinued treatment early while 7% of the participants receiving liraglutide discontinued treatment early, These findings were in comparison to only 3% of test subjects from the placebo group that discontinued treatment due to adverse events [1]
Cerevel and ImmunoGen acquisitions integrating #6 AstraZeneca plc (NASDAQ: AZN / LSE: AZ) AstraZeneca plc (NASDAQ: AZN
Oestreich LKL, Lyall AE, Pasternak O, Kikinis Z, Newell DT, Savadjiev P, et al
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits